Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (May 2024)

Transcatheter Mitral Valve Repair With the MitraClip Device for Prior Mitral Valve Repair Failure: Insights From the GIOTTO‐FAILS Study

  • Arturo Giordano,
  • Paolo Ferraro,
  • Filippo Finizio,
  • Nicola Corcione,
  • Michele Cimmino,
  • Giuseppe Biondi‐Zoccai,
  • Paolo Denti,
  • Antonio Popolo Rubbio,
  • Anna Sonia Petronio,
  • Antonio L. Bartorelli,
  • Annalisa Mongiardo,
  • Salvatore Giordano,
  • Francesco De Felice,
  • Marianna Adamo,
  • Matteo Montorfano,
  • Cesare Baldi,
  • Giuseppe Tarantini,
  • Francesco Giannini,
  • Federico Ronco,
  • Ida Monteforte,
  • Emmanuel Villa,
  • Maurizio Ferrario,
  • Luigi Fiocca,
  • Fausto Castriota,
  • Angelo Squeri,
  • Corrado Tamburino,
  • Francesco Bedogni

DOI
https://doi.org/10.1161/JAHA.123.033605
Journal volume & issue
Vol. 13, no. 10

Abstract

Read online

Background Minimally invasive mitral valve repair has a favorable risk–benefit profile in patients with significant de novo mitral regurgitation. Its role in patients with prior mitral valve repair is uncertain. We aimed to appraise the outcome of patients undergoing transcatheter edge‐to‐edge repair (TEER) with prior transcatheter or surgical mitral valve repair (SMVR). Methods and Results We queried the Italian multicenter registry on TEER with MitraClip, distinguishing naïve patients from those with prior TEER or (SMVR). Inhospital and long‐term clinical/echocardiographic outcomes were appraised. The primary outcome was the occurrence of death or rehospitalization for heart failure. A total of 2238 patients were included, with 2169 (96.9%) who were naïve to any mitral intervention, 29 (1.3%) with prior TEER, and 40 (1.8%) with prior SMVR. Several significant differences were found in baseline clinical and imaging features. Respectively, device success was obtained in 2120 (97.7%), 28 (96.6%), and 38 (95.0%, P=0.261) patients; procedural success in 2080 (95.9%), 25 (86.2%), and 38 (95.0%; P=0.047); and inhospital death in 61 (2.8%), 1 (3.5%), and no (P=0.558) patients. Clinical follow‐up after a mean of 14 months showed similar rates of death, cardiac death, rehospitalization, rehospitalization for heart failure, and their composite (all P>0.05). Propensity score–adjusted analysis confirmed unadjusted analysis, with lower procedural success for the prior TEER group (odds ratio, 0.28 [95% CI, 0.09–0.81]; P=0.019) but similar odds ratios and hazard ratios for all other outcomes in the naïve, TEER, and SMVR groups (all P>0.05). Conclusions In carefully selected patients, TEER can be performed using the MitraClip device even after prior TEER or SMVR.

Keywords